Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Core Insights - Eledon Pharmaceuticals announced positive 24-month follow-up data from a Phase 1b trial of tegoprubart in kidney transplantation, showing an increase in mean estimated glomerular filtration rate (eGFR) from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months [1][2] Company Overview - Eledon Pharmaceuticals is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, with its lead product being tegoprubart, an anti-CD40L antibody [3] - The company aims to leverage its expertise in anti-CD40 Ligand biology to conduct studies in various transplantation fields, including kidney allograft transplantation and amyotrophic lateral sclerosis (ALS) [3]